Amsacrine is an antineoplastic drug used in the treatment of acute adult leukemias. To assess its carcinogenic potential, groups of 50 male and 50 female rats were administered amsacrine by lateral tail vein injection at 0 (vehicle control), 0.25, 1, or 3 mg/ kg once daily for 5 days, followed by a 23-day recovery period. This cycle of dosing and recovery was repeated a total of six times. The animals were then maintained without dosing for an 18-month observation period. During the dosing phase, signs of toxicity were limited to the 3 mg/kg animals and included alopecia, diarrhea, injection site lesions, and skin and subcutaneous nodules. Statistically significant reductions in body weight gain and food consumption also occurred at 3 mg/kg during each 5-day dosing period followed by recovery during the latter 3 weeks of each cycle. Except for skin and subcutaneous nodules, signs of toxicity in the 3 mg/kg animals ultimately disappeared during the 18-month observation phase. Survival at study termination for the vehicle control, 0.25, 1, and 3 mg/kg groups was 56, 52, 34, and 0%, respectively, in males, and 64, 48, 54, and 4%, respectively, in females. Mortality was primarily due to bone marrow suppression during the dosing phase, chronic progressive nephropathy, or development of tumors. Incidences of the following tumors were significantly increased in the 3 mg/kg groups of both sexes (Fisher exact test, two-tailed, p < 0.01): all malignancies; all tumors of the small intestine, adenocarcinoma and adenoma of the small intestine, all tumors of the skin, and squamous cell papilloma. Other tumor incidences that were significantly increased in the 3 mg/kg males were thymoma and multiple neoplastic histotypes of the skin and adnexa including basal cell tumor, fibroma, sebaceous gland adenoma, and squamous cell carcinoma. A disproportionate number of the skin tumors were located on the tail, suggesting a localized tissue concentration effect. In the 3 mg/kg females, significantly increased tumor incidences also included all tumors of the mammary gland, adenocarcinoma of the mammary gland, all tumors of the uterine horn, and endometrial stromal polyps of the uterine horn. The 1 mg/kg males had significantly increased incidences of all tumors of the small intestine and skin, adenocarcinoma of the small intestine, and fibroma of the skin. Fibroma of the skin was also significantly increased in the 0.25 mg/kg males. Incidences of all tumors and all benign tumors were significantly increased in the 1 mg/kg females. There were no significantly increased tumor incidences in the 0.25 mg/kg females. The results of this study show that amsacrine is carcinogenic in Wistar rats. Target organs for tumorigenicity include small intestine, skin, mammary gland, thymUS, and UterUS.
of the skin tumors were located on the tail, suggesting a localized tissue concentration effect. In the 3 mg/kg females, significantly increased tumor incidences also included all tumors of the mammary gland, adenocarcinoma of the mammary gland, all tumors of the uterine horn, and endometrial stromal polyps of the uterine horn. The 1 mg/kg males had significantly increased incidences of all tumors of the small intestine and skin, adenocarcinoma of the small intestine, and fibroma of the skin. Fibroma of the skin was also significantly increased in the 0.25 mg/kg males. Incidences of all tumors and all benign tumors were significantly increased in the 1 mg/kg females. There were no significantly increased tumor incidences in the 0.25 mg/kg females. The results of this study show that amsacrine is carcinogenic in Wistar rats. Target organs for tumorigenicity include small intestine, skin, mammary gland, thymUS, and UterUS. © 1996 Society of Toxicology Amsacrine (m-AMSA; Fig. 1 ) is a synthetic 9-aminoacridine derivative with clinical activity against acute lymphocytic and nonlymphocytic leukemias (Arlin et al, 1980; Legha et al, 1982; Arlin et al, 1988; Arlin, 1989; Jehn and Heineman, 1991) . Although amsacrine is a weak DNA intercalator, its mechanism of action is primarily due to inhibition of the nuclear enzyme topoisomerase II (Zwelling et al, 1981; Nelson et al, 1984; Pommier et al, 1984; Minford etal, 1986; Rowe etal, 1986; Cummings and Smyth, 1993) . Topoisomerase II is involved in the relaxation of supercoiled DNA during cellular replication and transcription and acts by unlinking and rejoining two intertwined DNA strands (Liu, 1989) . In the presence of amsacrine, topoisomerase II becomes trapped as part of a DNA-enzyme cleavable complex leading to the formation of protein-linked DNA strand breaks and cross-links (Zwelling et al, 1981; Nelson et al, 1984; Pommier et al, 1984 Pommier et al, , 1987 Minford et al, 1986; Liu, 1989) . Topoisomerase II DNA strand breaks have been associated with the cytotoxicity observed in amsacrinetreated L1210 leukemia cells (Rowe et al, 1986; Covey et al, 1988) .
Although amsacrine has clinical activity as a single agent, it is almost exclusively used in combination with cytarabine in the treatment of refractory and relapsed acute leukemias GRAZ1ANO ET AL. in adults where complete response rates of up to 70% have been achieved (Hines et al, 1984; Arlin et al, 1988; Arlin, 1989; Zittoun^a/., 1989; Dekker etal, 1990; Spinoloef al, 1990; Freund et al, 1991; Miller et al, 1991) . Amsacrine's importance in treating adult leukemias has been recognized since it is safe and effective in patients with myocardial dysfunction (Arlin et al, 1991; Maschmeyer et al, 1992) . In maintenance therapy, amsacrine is often administered as repetitive courses of treatment over several months. In one study, amsacrine was administered for 5 consecutive days at 4-week intervals (Legha et al, 1982) . In another study, amsacrine was administered in combination with either cytarabine or 5-azacytidine in six courses at 6-week intervals (Zittoun et al., 1989) .
As chemotherapeutic regimens are optimized, long-term remissions of adult leukemias may be achieved. This, in turn, will necessitate investigations on the chronic toxicity of antineoplastic drugs in order to more completely assess their safety following prolonged and/or repeated administration. In the case of amsacrine, chronic safety studies are important not only because of its continued use and clinical effectiveness, but also because of its mutagenic and clastogenic properties (DeMarini et al, 1987; Andersson and Kihlman, 1989; Backer et al, 1990; Holstrom and Winters, 1992) . The carcinogenicity of many antineoplastic drugs has been recognized for some time and secondary tumors have been associated with their use (Rieche, 1984; Kaldor et al, 1988; Marselos and Vainio, 1991) . Therefore, the objective of this study was to assess the potential carcinogenicity of amsacrine in rats following a clinical dosing schedule. The doses in the present study were based on the results of a 6-month range-finding study in rats. A detailed description of amsacrine's chronic toxicity, including target organ effects, is provided in a separate report (Pegg et al, 1996) .
METHODS

Animals.
Male and female Wistar rats (Crl: (WI)BR) were obtained from Charles River Laboratories (Portage. MI). The animals were observed for 1 to 2 weeks prior to initiation of the study to ensure that they were healthy and acclimated to the laboratory environment. Animals in a clinically acceptable condition were randomized to the various treatment groups. There were no statistically significant differences in body weights between treatment groups following randomization (p =6 0.01). At initiation of dosing, all animals were 6 to 8 weeks old; group mean body weights were 189 ± 3 g for males and 146 ± 2 g for females. The animals were housed individually in suspended stainless steel wire mesh cages. Once a week, the animals were fed 180 g of powdered Purina Certified Rodent Chow 5002 (Ralston Purina, St. Louis, MO) in stainless steel food containers. Water was supplied ad libitum by means of an automatic watering system. The animals were maintained in environmentally controlled rooms with a 12-hr light/dark cycle.
Test article and administration.
Amsacrine was supplied by ParkeDavis Company as a dipack consisting of an ampule of 75 mg of active drug (98.9% punty) in 1.5 ml of anhydrous /V,/V-dimethylacetamide (DMA) and a sterile vial of 13.5 ml of 0.0363 M lactic acid diluent. All materials were formulated to meet requirements for human clinical administration. The chemical identity of amsacrine was confirmed by comparison to a reference standard using infrared and ultraviolet spectrophotometry, and thin layer chromatography. Dosing solution for the 3 mg/kg groups was prepared by adding 1.5 ml of drug/DMA to 13.5 ml of lactic acid diluent. Dosing solutions for the 0.25 and 1 mg/kg groups were prepared by further diluting the drug/DMA/lactic acid diluent with 5% Dextrose for Injection, USP. Control vehicle was prepared identically to the 3 mg/kg dosing solution except that amsacrine was not included in the DMA ampule. Stability of amsacrine in DMA and in the diluted solutions was confirmed analytically. The dosing solutions were administered by lateral tail vein injection at a dose volume of 0.6 ml/kg and a dose rate of 0.1 ml/10 sec. Vehicle control animals received the same dose volume as the treated animals. All dosing solutions were prepared daily and were analyzed for confirmation of drug concentrations twice weekly. Except for a few sporadic low dose samples, all dosing solutions were within 10% of intended concentrations.
Experimental design. Rats were administered intravenous doses of amsacrine once each day for 5 consecutive days, followed by a 23-day recovery period without dosing. This cycle of dosing and recovery was repeated a total of six times. The animals were then maintained without dosing for the remainder of the 104-week study. Each dose group consisted of 50 rats per sex Doses were 0 (vehicle control), 0.25, 1, and 3 mg/kg (0, 1.5, 6, and 18 mg/m 2 , respectively; Freireich et al, 1966) .
Clinical observations. Animals were observed daily for clinical signs. Detailed physical examinations including palpation for masses were performed monthly. Ophthalmic examinations were conducted pretest and at 26-week intervals throughout the study. Body weights were measured each day prior to dosing, weekly throughout the remainder of the study, and at the time of necropsy. Food consumption was recorded weekly.
Clinical laboratory tests. Hematology and clinical biochemistry determinations were performed on blood samples collected by cardiac puncture from all animals at moribund and scheduled necropsies. Urinalyses were performed on samples collected overnight prior to scheduled necropsies. Bone marrow samples were taken from all animals at necropsy and evaluated by flow cytometry. All clinical laboratory tests were performed using automated instrumentation except urine sediment which was examined microscopically.
Pathology. All animals were euthanatized by ether inhalation. For pur poses of statistical evaluations, moribund animals were considered deaths. Complete gross examinations were performed on all animals. Representative specimens from all major tissues and gross lesions were collected at necropsy, fixed in 10% buffered formalin (except as noted), processed, stained with hematoxylin and eosin (H & E) . and examined by light microscopy. Eyes were fixed in 6% glutaraldehyde and the male reproductive tract was fixed in Bouin's.
Statistical analysis.
For all nontumor parameters (except survival data), treatment comparisons were performed using either Student's t test or a one-factor analysis of variance dose trend test (rank-transformed data). Both tests were performed at the two-tailed 1% significance level (p < 0.01). The survival percentage for each group was estimated by the product-limit method as described by Kaplan and Meier (1958) . For purposes of statistical evaluation, all animals euthanatized in moribund condition were considered deaths. Differences in survival among groups and survival dose-response trends were assessed by the methods of Tarone and Ware (1977) and Tarone (1975) , respectively. These latter tests were performed at the two-tailed 5% significance level {p < 0.05).
The statistical evaluation of tumor incidence was done in two stages and was based on principles outlined by Peto et al. (1980) and Gart et al. (1979) . The first stage of analysis consisted of the Peto dose-trend test conducted at the two-tailed 10% significance level (p < 0.10). Tumor categories identified as statistically significant were then analyzed in a second stage of statistical tests performed at the two-tailed 1% significance level (p < 0.01). These tests included a comparison of each treated group to the controls using the Fisher exact test (Armitage, 1974a) , a dose-trend test using the Armitage x 2 method (Armitage, 1974b) , and an analysis of tumor occurrence by life-table methods (Tarone and Ware, 1977; Peto et al., 1980 ). Fisher's exact test was used as the primary statistical test for assigning tumor significance and was based on the proportion of tumor bearing animals among the animals at risk. Animals considered at risk were those alive at the first occurrence of the tumor type among animals of the same sex. All statistical analyses were performed separately for each sex.
RESULTS
Clinical Observations
During the dosing phase, only sporadic clinical signs were observed in the vehicle control, 0.25, and 1 mg/kg groups. In contrast, almost all of the 3 mg/kg animals exhibited signs of toxicity including generalized hair loss, diarrhea, injection site injuries and related tail lesions (erythema, swelling, loss of tail tip), subcutaneous and skin nodules, and swelling of the head and ventral cervical region. Diarrhea occurred several days following each dose but was not observed during the remainder of each dosing cycle. The injection site/tail lesions and generalized hair loss gradually subsided following the dosing phase and eventually disappeared. Nodules appeared as early as Week 7 and rapidly increased in both size and incidence.
During the 18-month observation phase, clinical signs were observed in all groups although the 3 mg/kg animals were the most severely affected. The most frequently observed findings were skin and subcutaneous nodules. The incidence of animals with nodules was 42, 40, 66, and 90% in the vehicle control, 0.25, 1, and 3 mg/kg males, respectively; corresponding incidences in the female groups were 34, 34, 50, and 86%, respectively. Skin nodules appeared most often on the head, tail, and dorsalthoracic areas, whereas subcutaneous nodules were more predominant in the ventral-thoracic, abdominal, and inguinal regions. Other clinical signs were nonspecific and associated with morbidity. FIG. 2. Survival percentages of male and female rats administered amsacrine. Animals were administered amsacrine intravenously once a day for 5 consecutive days, followed by a 23-day recovery period. This cycle of dosing and recovery was repeated a total of six times. The animals were then maintained without dosing for an 18-month observation phase. Survival was significantly less than the corresponding vehicle controls in the 1 mg/ kg males (p < 0.015) and in the 3 mg/kg males and females (p < 0.0001).
Mortality
A statistically significant decrease in survival was observed in the 1 mg/kg males (p < 0.015) and in the 3 mg/kg males and females (p < 0.0001). Survival at study termination for the vehicle control, 0.25, 1, and 3 mg/kg groups was 56, 52, 34, and 0%, respectively, for the males, and 64, 48, 54, and 4%, respectively, for the females (Fig.  2) . Survival was decreased by more than 10% as early as Week 39 for the 3 mg/kg males and Week 18 for the 3 mg/ kg females. For all other groups, survival was not decreased by more than 10% until after Week 60. Two 3 mg/kg animals (one male and one female) appeared to have died from druginduced bone marrow atrophy in Weeks 2 and 22. End-stage renal disease (grade 4 CPN) was considered a cause of death for 2, 8, 7, and 13 males in the vehicle control, 0.25, 1, and Animals were administered amsacrine intravenously once a day for 5 consecutive days, followed by a 23-day recovery period. This cycle of dosing and recovery was repeated a total of six times. The animals were then maintained without dosing for an 18-month observation phase. Body weight data are not shown beyond Week 52 due to the high level of mortality in the 3 mg/kg groups.
3 mg/kg groups, respectively, and for 4 females at 3 mg/kg. Most other deaths were attributed to tumor burden.
Body Weights
Statistically significant reductions in body weight gain (relative to controls) or actual body weight loss occurred in the 3 mg/kg groups during each 5-day dosing period (p < 0.01; Fig. 3 ). During the latter 3 weeks of each recovery cycle, body weight gain for these groups was comparable to or exceeded control levels. Nonetheless, mean body weights for the 3 mg/kg groups remained statistically lower than the vehicle controls throughout most of the study. Statistically significant reductions in body weight gain and/or reduced mean body weights were also observed sporadically in the 1 mg/kg males during the 6-month dosing phase. Body weights remained fairly constant during the observation phase of the study, although comparisons beyond Week 52 were not considered meaningful due the high incidence of mortality, especially in the 3 mg/kg animals.
Food Consumption
Changes in food consumption essentially paralleled the effects on body weights. In the 3 mg/kg groups, food consumption was significantly reduced by 29 to 55% relative to the controls during the 5-day dosing periods and increased to or exceeded control levels during the latter 3 weeks of each cycle (data not shown). Food consumption by the 1 mg/kg males was also significantly reduced by 3 to 17% in 5 of the 6 dosing weeks. During the observation phase, statistically significant reductions in food consumption occurred sporadically in the 3 mg/kg males. These latter findings were most likely attributed to the higher morbidity rate in this group.
Clinical Laboratory Parameters
There were no clinically significant changes in hematology, bone marrow, biochemistry, or urinalysis parameters in the 0.25 or 1 mg/kg groups at study termination (data not shown). Lack of surviving animals precluded analysis of the 3 mg/kg groups.
Nonneoplastic Pathology
The incidence of significant nonneoplastic histopathology findings is presented in Table 1 . An increased incidence of bone marrow atrophy and/or hypocellularity was seen in the 3 mg/kg groups of both sexes. Bone marrow atrophy was most pronounced in animals that died during the 6-month dosing period. Drug-induced testicular degeneration which progressed to diffuse atrophy of spermatogenic epithelium was present in more than 40% of the 3 mg/kg males. The incidence of end-stage renal disease or grade 4 chronic progressive nephropathy (CPN) was also increased in the 3 mg/ kg males and females and ultimately contributed to the higher mortality in these groups. CPN was characterized by marked, diffuse, glomerular, and tubular changes involving more than 75% of the parenchyma. Principal tubular changes included basophilic tubules with or without thickened basement membranes, intraluminal protein casts, tubular dilatation, and basophilic or eosinophilic tubular regeneration and/ or hyperplasia. Glomerular changes included sclerosis, atrophy, crescent formation, and mesangial thickening. Other microscopic findings of CPN were interstitial mononuclear cell infiltrates, fibroplasia, and transitional cell hyperplasia.
Dose-related increased incidences of bone marrow erythroid, myeloid, and/or pancytic hypercellularity were observed at all doses in the males, and at 3 mg/kg in the females. These findings were most commonly seen as secondary changes in animals with tumors in other organs (often ulcerated) and were usually accompanied by extramedullary hematopoiesis. Other secondary changes included an increased incidence of extramedullary hematopoiesis in adrenal, liver, and/or spleen in all male and female drug-treated groups; a dose-related increased incidence of pancreatic polyarteritis in males and females; an increased incidence of fibrous osteodystrophy in the 3 mg/kg males; and an increased incidence of Harderian gland hyperplasia in the 3 mg/kg males and females. The pancreatic polyarteritis and fibrous osteodystrophy were associated with end-stage renal disease.
Neoplastic Pathology
Overall, 80 specific tumor types were identified in the males and 81 were identified in the females. These were grouped into 200 tumor categories for statistical analysis. Of these, 72 were significant for a positive dose trend at the first stage of statistical testing (Peto test, two-tailed, p < 0.1). At the second stage of testing (two-tailed, p < 0.01), 40 tumor categories were significant for a positive dose-trend by Peto analysis, 24 were significant by Armitrage analysis, and 38 were significant by Tarone analysis (Table 2) .
From the results of the Fisher exact test (two-tailed, p < 0.01), incidences of the following tumors types/categories were significantly increased in the 3 mg/kg males: all malignancies, all tumors of the small intestine, adenocarcinoma of the small intestine, adenoma of the small intestine, thymoma, all tumors of the skin, basal cell tumor of the skin, fibroma of the skin, sebaceous gland adenoma of the skin, and squamous papilloma of the skin. A relatively large number of the skin tumors were located on the tails. The 1 mg/kg males had significantly increased incidences of all tumors of the small intestine, all tumors of the skin, adenocarcinoma of the small intestine, and fibroma of the skin. The 0.25 mg/kg males also had a significantly increased incidence of skin fibroma.
In the 3 mg/kg females, significantly increased tumor incidences by the Fisher exact test included all malignancies, all tumors of the mammary gland, adenocarcinoma of the mammary gland, all tumors of the small intestine, adenocarcinoma of the small intestine, adenoma of the small intestine, all tumors of the skin, squamous papilloma of the skin, all tumors of the uterine horn, and stromal polyps of the uterine horn. As in the males, a relatively large number of skin tumors were located on the tail. Incidences of all tumors and all benign tumors were significantly increased in the 1 mg/ kg females. There were no significantly increased tumors in the 0.25 mg/kg females.
Most of the amsacrine-induced tumors in this study were similar morphologically to those that arise spontaneously in the Wistar rat. One notable exception was a granular basal cell tumor of the skin, the morphological characteristics of which were described in an earlier report (Courtney et al., 1992a) . The small intestinal adenocarcinomas were noteworthy given their rarity in the Wistar rat (Walsh and Poteracki, 1994) . These malignant tumors showed a variable growth pattern such that histotype from both polyps (Fig. 4) and flat mucosa (Fig. 5) were observed. Small intestinal adenocarcinomas from four 3 mg/kg males metastisized to regional lymph nodes, liver, lung, and spleen (Gough et al., 1994) .
A marked decrease in the incidence of adenoma of the anterior pituitary was present in the 3 mg/kg groups. Adenoma of the anterior pituitary gland is a common age-related finding in laboratory rats and the decreased incidence at 3 mg/kg reflects the earlier mortality in these groups.
DISCUSSION
The results of this study demonstrate that amsacrine is carcinogenic in Wistar rats following a repeated-cycle intravenous dosing schedule. Target organs were skin, small in- 
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Rats were administered amsacrine intravenously once a day for 5 consecutive days followed by a 23-day recovery period. This cycle of dosing and recovery was repeated a total of six times. The animals were then maintained without dosing for an 18-month observation phase.
* testine, mammary gland, thymus, and uterus. The results also demonstrate a clear dose response to the carcinogenic effects. At 3 mg/kg, 10 statistically significant tumor categories (Fisher exact test, two-tailed, p < 0.01) were identified in males, and 10 were identified in females. At 1 mg/kg, four statistically significant tumor categories were identified in males and two in females. The only statistically significant tumor category identified at 0.25 mg/kg was skin fibroma in the males. The equivalent body surface area doses of amsacrine administered in the present study were 1.5, 6, and 18 mg/m 2 . In contrast, the standard therapeutic dose of amsacrine ranges from 100 to 200 mg/m 2 (Hines et al, 1984; Arlin et al, 1988; Willemze et al, 1988; Dekker et al, 1990; Arlin et al., 1991) , although lower doses of 30 to 40 mg/m 2 have been used in maintenance therapy (Legha et al., 1982) . Since 18 mg/m 2 is approximately 2-to 10-fold lower than the clinical therapeutic dose, it would appear that humans are receiving doses well above those that are carcinogenic in rats. However, relative to humans, rats appear to be more sensitive to the effects of amsacrine since 18 mg/m 2 exceeded a maximum tolerated dose in the present study. This raises the question of whether the rat may be overpredicting the carcinogenic potential of amsacrine in humans based on direct comparisons of body surface area doses. When the doses are compared on a body weight basis, however, there seems to be much closer agreement between the two species. For example, using an average body weight to body surface area conversion factor of 37 for humans (Freireich et al., 1966) , clinical doses of amsacrine range from 0.8 to 5.4 mg/ kg. This is certainly within the range of doses administered in the present study, i.e., 0.25 to 3 mg/kg. Assuming that the clinical use of amsacrine is at or near its maximum tolerated dose, then the rat may indeed be a relevant model for quantitatively estimating the carcinogenic potential of amsacrine if dose comparisons are made on a body weight basis. A recent analysis of carcinogenicity potency data in rodents and humans does suggest that exposure in rodent carcinogenicity studies is best expressed in terms of mg/kg of body weight (Monro and Mordenti, 1995) .
The carcinogenicity of amsacrine is consistent with its mechanism of action. Amsacrine induces protein-linked DNA strand breaks and cross-links through inhibition of DNA topoisomerase II (Zwelling et al., 1981; Nelson et al., 1984; Pommier et al, 1984 Pommier et al, , 1987 Minford et al, 1986; Rowe et al, 1986; Covey et al, 1988; Liu, 1989) and is mutagenic in a number of different test systems (Lim et al, 1986; DeMarini et al, 1987; Andersson and Kihlman, 1989; Holmstrom and Winters, 1992; Iwamoto et al, 1992) . Since it is well established that many chemical carcinogens involve interaction with DNA and that most DNA-reactive chemicals are also mutagens, the identification of amsacrine as a rodent carcinogen was not unexpected. Many other structurally diverse anticancer drugs are also known or suspected carcinogens (Rieche, 1984; Kaldor et al, 1988; Marselos and Vainio, 1991) . The carcinogenicity of amsacrine may also be FIG. 4 . Polypoid growth pattern of a small intestinal adenocarcinoma in a male rat treated with amsacrine at 3 mg/kg. Border of tumor (arrows) directly opposed to normal mucosal surface. Scale bar, 0.5 cm.
due, at least in part, to its apparent immunosuppressive properties. Since amsacrine is cytotoxic to bone marrow and lymphoid tissue, immunosurveillance of transformed cells may be compromised, thereby leading to an increased incidence of tumors. An association between chemical-or viralinduced immunosuppression and an increased risk of tumor development has been observed in both humans and laboratory animals (Ryffel et al., 1992; Spina and Tirelli, 1992; Gallo et al., 1993; Mather et al., 1994) .
The number of different target organs identified in this study is consistent with the expected effects of a mutagen (Ashby and Tennant, 1988; Gold et al., 1993; Haseman and Lockhart, 1993) . Ashby and Tennant (1988) reviewed the results of 222 chemicals evaluated for rodent carcinogenicity by the National Cancer Institute and the National Toxicology Program and concluded that multitissue involvement is characteristic of genotoxic carcinogens. In the rat, target tissues included Zymbal's gland, mammary gland, lung, skin, circulatory system, and possibly the uterus and clitoral gland. Consistent with these findings, mammary gland, skin, and uterus were also identified as target sites in the present study. A more recent review of the Carcinogenicity Potency Database by Gold et al. (1993) showed that the eight most frequent target sites for genotoxic carcinogens are liver, lung, mammary gland, stomach, vascular system, kidney, hematopoietic system, and urinary bladder. Except for the mammary gland, none of these tissues were identified as tumor sites for amsacrine. The most common target sites identified by reviews of carcinogenicity databases, however, are generalizations and there are numerous examples of individual compounds which exert carcinogenic effects on other tissues. For example, in the review by Gold et al. (1993) , 11 different mutagens were classified as carcinogenic to the rat small intestine even though the small intestine was not considered a common target site within the context of the entire database. Similarly, 13 mutagens were identified as skin carcinogens in rats, and 6 mutagens were identified as carcinogens for the rat uterus. In a review of the carcinogenic properties of pharmaceutical agents, Marselos and Vainio (1991) list   FIG. 5 . Small intestinal adenocarcinoma derived from flat mucosa in a male rat treated with amsacrine at 3 mg/kg. Scale bar, 0.5 cm.
the reported target sites of antineoplastic drugs in rodents which were either known, probable, or possible human carcinogens. Although target organs for tumorigenicity varied from study to study and were dependent upon species (i.e., mice or rats), route of administration, and individual drug, mammary gland, bone marrow, lymphatic tissue, kidney, peritoneum, skin, and lung appeared to be the most frequently observed target sites in rats by all routes of administration. Tumors of the small intestine and uterus were not common.
For other structural classes of acridines, only the benzacridines and acridine-carried alkylators have been demonstrated to be carcinogenic in animals (Ferguson and Denny, 1991) . The carcinogenic activity of the benzacridines, however, appears to be dependent upon metabolic activation to bay-region diol epoxides and is not related to the acridine ring per se (Lehr et al., 1988) . As such, the carcinogenic mechanism of this class of acridines is similar to the polycyclic aromatic hydrocarbons. Acridine-carried alkylators were carcinogenic in the lung tumor bioassay in strain A mice following intravenous but not intraperitoneal administration (Peck et al., 1976) . The alkylating moiety of this series of acridines consists of aliphatic nitrogen mustards and it is not clear which portion of the molecule is actually inducing the carcinogenic effect. More conventional bioassays have not been conducted on this structural series. No carcinogenicity studies have been conducted with any of the of 9-aminoacridines, quaternary acridines, or nitroacridines. Of these, only the nitroacridines are considered genotoxic based on in vitro data (Ferguson and Denny, 1991) . Limited evidence of proflavine (3,6-diaminoacridine) carcinogenicity was seen in both rat and mouse bioassays, although due to inadequacies in the experimental design of these studies, a firm conclusion on the carcinogenicity of proflavine could not be reached (National Cancer Institute, 1977) . Based on the results of the present study, the 9-anilinoacridines must be considered probable carcinogens, particularly if they demonstrate mutagenic or clastogenic activity. The carcinogenicity of amsacrine is most likely related to topoisomerase II inhibition and not DNA intercalation since all acridines are DNA intercalators to some degree, yet there is little or no evidence for carcinogenicity related to this property. In addition, DNA intercalation in and of itself is not completely sufficient for the biological effects of 9-anilinoacridines (Ferguson and Denny, 1991) .
Although most carcinogens induce tumors in multiple organs, it is not clear why amsacrine would selectively increase tumor incidences in the small intestine, mammary gland, skin, thymus, and uterus. It might be speculated that amsacrine is promoting cellular proliferation in these tissues due to direct cytotoxic injury, thereby increasing the frequency of spontaneous tumors or tumors initiated by amsacrine itself. This is thought to be a common cause of tumor induction in rodent carcinogen bioassays, especially when positive results are obtained in target organs of toxicity and at the maximum tolerated dose (Ames and Gold, 1990; Carr and Kolbye, 1991; Clayson et al., 1991) . The mammary gland and uterus do have a high frequency of spontaneous tumors in the Wistar rat relative to most other organs (Bomhard and Rinke, 1994; Walsh and Poteracki, 1994) . However, except for thymus and small intestine, none of the tissues with increased tumor incidences in the present study have been identified as target organs of amsacrine toxicity (Henry et al., 1980; Pegg et al., 1996) . Therefore, for some of the tumor findings, amsacrine carcinogenesis appears inconsistent with a promotion mechanism. Other organs which are target sites of amsacrine toxicity, such as the liver, bone marrow, and testes did not have increased tumor frequencies. These latter results were surprising since the liver and hematopoietic system are also common tumor sites for genotoxic chemicals in general.
The high incidence of skin and small intestinal tumors in this study may have been due to localized tissue concentration effects at the site of injection or as a result of biliary excretion, respectively. In both mice and rats, more than 50% of a radiolabeled dose of amsacrine is excreted in the bile within 2 hr after intravenous administration, and more than 80% of radioactivity can be recovered in the feces of mice after 72 hr (Cysyk et al., 1977) . Thus, high levels of amsacrine can occur in the small intestine due to its biliary route of excretion and recirculation (Cysyk et al., 1977) . The histopathologic features of some of the more unusual tumors identified in this study, including granular cell tumors of the female reproductive tract, a granular basal cell tumor of the skin, and small intestinal adenocarcinomas, have been described (Courtney et al, 1992a,b; Gough et al., 1994) .
In conclusion, amsacrine was carcinogenic in male and female Wistar rats following a repeated-cycle dosing schedule. Carcinogenicity was evident based on statistically significant dose-related increased incidences of multiple malignant tumors along with shortened latency periods. Target organs for tumorigenicity were small intestine, mammary gland, skin, thymus, and uterine horn. The clinical implication of these results must be considered in context of the probable disease outcome in patients and available alternative therapies.
